Clinical Trial Update: Study of CTDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/Phase 3 clinical trial is investigating CTDNA response-guided adaptive immuno-chemotherapy for lung cancer. The study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Cancer

Snippet

Sponsor: Canadian Cancer Trials Group | Conditions: Lung Cancer | Phase 2, Phase 3 | Status: RECRUITING